A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study of Regorafenib in Patients With Hepatocellular Carcinoma (HCC) After Sorafenib
收藏DataCite Commons2025-09-02 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00008416/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The objective of this study was to evaluate efficacy and safety of regorafenib in patients
with advanced liver cancer who had progressed after sorafenib treatment. Patients were
treated with regorafenib or placebo using a 2:1 randomization scheme.
提供机构：
Vivli
创建时间：
2022-09-02
